Active, not recruitingPhase 3NCT06901505

To Evaluate the Efficacy of Three Times Weekly (TIW) Vadadustat Compared to Standard of Care ESA in Patients With Anemia of CKD Receiving In-Center Hemodialysis

Studying Complication in hemodialysis

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Akebia Therapeutics
Intervention
Erythropoiesis-Stimulating Agent (ESA)(drug)
Enrollment
353 target
Eligibility
18 years · All sexes
Timeline
2025 – 2026

Study locations (18)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06901505 on ClinicalTrials.gov

Other trials for Complication in hemodialysis

Additional recruiting or active studies for the same condition.

See all trials for Complication in hemodialysis →

← Back to all trials